Drugging RNA

How RNA play Arrakis plans to spend its $38M series A round

With a tranched $38 million series A round led by Canaan Partners, Arrakis Therapeutics Inc. is putting an initial set of hits into preclinical development, and building out a platform that will allow it to systematically screen for small molecules that bind RNA targets, a

Read the full 453 word article

How to gain access

Continue reading with a
two-week free trial.